Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 12:43 AM
Ignite Modification Date: 2025-12-25 @ 12:43 AM
NCT ID: NCT00776867
Eligibility Criteria: Inclusion Criteria: * Any solid tumor that failed standard therapy. * Patient must have evidence for tumor by CT, MRI, PET scan, MIBG scan, serum markers, or tissue sampling. * Age ≤ 21 years. * Karnofsky/Lansky performance status ≥ 50% (Karnofsky score for age\> 16 years and Lansky score for age ≤ 16 years) * ANC≥ 1000 at least 24 hours off GCSF * Platelets ≥ 75k at least one week off platelet transfusions * Hg≥ 8g/dL at least one week off PRBC transfusion * AST ≤ 3 x the upper limit of normal * ALT ≤ 3 x the upper limit of normal * Total bilirubin ≤ 2.0 mg/dl * serum creatinine ≤ 1.5 x the upper limit of normal for age, or calculated creatinine clearance or nuclear GFR ≥ 70 ml/min/1.73 m2. * ≥ 3 weeks since last non-nitrosourea chemotherapy * ≥ 6 weeks since last nitrosoureas * ≥ 4 weeks since last RT * Patients must agree to practice adequate contraception. Females of childbearing potential must have a negative B-HCG pregnancy test documented within 14 days prior to drug initiation. Females must not be breast feeding. * Patients must be able to swallow tablets whole Exclusion Criteria: * Pregnancy * Patients must not have active infection or serious intercurrent medical illness. * HIV-Positive patients receiving combination anti-retroviral therapy are excluded from the study due to possible retro-viral drug interactions. HIV testing not required. * Patients must not be taking EIAEDs. If patients were previously EIAEDs that have been discontinued, patients must have been off the agent for at least 2 weeks prior to registration.
Healthy Volunteers: False
Sex: ALL
Maximum Age: 21 Years
Study: NCT00776867
Study Brief:
Protocol Section: NCT00776867